

REGENERON PHARMACEUTICALS INC

Form 4

August 17, 2015

**FORM 4****UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

Check this box  
if no longer  
subject to  
Section 16.  
Form 4 or  
Form 5  
obligations  
may continue.  
See Instruction  
1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF  
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB  
Number: 3235-0287  
Expires: January 31,  
2005  
Estimated average  
burden hours per  
response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
Powchik Peter

(Last) (First) (Middle)

777 OLD SAW MILL RIVER  
ROAD

(Street)

TARRYTOWN, NY 10591

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading  
Symbol  
REGENERON  
PHARMACEUTICALS INC  
[REGN]

3. Date of Earliest Transaction  
(Month/Day/Year)  
08/13/2015

4. If Amendment, Date Original  
Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to  
Issuer

(Check all applicable)

\_\_\_\_ Director \_\_\_\_ 10% Owner  
\_X\_ Officer (give title below) \_\_\_\_ Other (specify below)  
SVP Clinical Development & Reg

6. Individual or Joint/Group Filing(Check  
Applicable Line)  
\_X\_ Form filed by One Reporting Person  
\_\_\_\_ Form filed by More than One Reporting  
Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
			Code	V	Amount	(A) or (D)	Price		
Common Stock	08/13/2015		M		10,000	A	\$ 270.43	25,821	D
Common Stock	08/13/2015		F		4,667	D	\$ 579.35	21,154	D
Common Stock	08/13/2015		F		2,749	D	\$ 579.35	18,405	D
Common Stock	08/13/2015		M		14,625	A	\$ 179.13	33,030	D
	08/13/2015		F		4,521	D		28,509	D

Edgar Filing: REGENERON PHARMACEUTICALS INC - Form 4

Common Stock					\$ 579.35		
Common Stock	08/13/2015	F	5,210	D	\$ 579.35	23,299	D
Common Stock	08/13/2015	M	23,000	A	\$ 52.03	46,299	D
Common Stock	08/13/2015	F	2,065	D	\$ 579.35	44,234	D
Common Stock	08/13/2015	F	10,795	D	\$ 579.35	33,439	D
Common Stock	08/13/2015	M	8,000	A	\$ 52.03	41,439	D
Common Stock	08/13/2015	F	718	D	\$ 579.35	40,721	D
Common Stock	08/13/2015	F	3,755	D	\$ 579.35	36,966	D
Common Stock	08/13/2015	M	4,736	A	\$ 30.63	41,702	D
Common Stock	08/13/2015	F	250	D	\$ 579.35	41,452	D
Common Stock	08/13/2015	F	2,146	D	\$ 579.35	39,306	D
Common Stock	08/14/2015	S	1,405	D	\$ 569.63 (1)	37,901	D
Common Stock	08/14/2015	S	3,603	D	\$ 570.63 (2)	34,298	D
Common Stock	08/14/2015	S	5,598	D	\$ 571.54 (3)	28,700	D
Common Stock	08/14/2015	S	2,800	D	\$ 572.6 (4)	25,900	D
Common Stock	08/14/2015	S	2,717	D	\$ 573.64 (5)	23,183	D
Common Stock	08/14/2015	S	900	D	\$ 574.75 (6)	22,283	D
Common Stock	08/14/2015	S	700	D	\$ 575.47 (7)	21,583	D

Edgar Filing: REGENERON PHARMACEUTICALS INC - Form 4

Common Stock	08/14/2015	S	2,004	D	\$ (8)	576.65	19,579	D	
Common Stock	08/14/2015	S	2,258	D	\$ (9)	577.75	17,321	D	
Common Stock	08/14/2015	S	1,500	D	\$ (10)	578.63	15,821	D	
Common Stock							12,890	I	by GRAT
Common Stock							1,652	I	By 401(k) Plan

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Security (Instr. 3 and 4)			
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Qualified Stock Option (right to buy)	\$ 30.63	08/13/2015		M		4,736		(11)	12/14/2020	Common Stock	4,736
Non-Qualified Stock Option (right to buy)	\$ 52.03	08/13/2015		M		23,000		(12)	12/16/2021	Common Stock	23,000
Non-Qualified Stock Option (right to buy)	\$ 52.03	08/13/2015		M		8,000		(11)	12/16/2021	Common Stock	8,000
Non-Qualified Stock Option (right to buy)	\$ 179.13	08/13/2015		M		14,625		(13)	12/14/2022	Common Stock	14,625

Non-Qualified Stock Option (right to buy)	\$ 270.43	08/13/2015	M	10,000	<u>(13)</u>	12/13/2023	Common Stock	10,0
---	-----------	------------	---	--------	-------------	------------	-----------------	------

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Powchik Peter 777 OLD SAW MILL RIVER ROAD TARRYTOWN, NY 10591			SVP Clinical Development & Reg	

## Signatures

/s/\*\*Peter  
Powchik

08/17/2015

\_\_Signature of  
Reporting Person

Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Represents volume-weighted average price of sales of 1,405 shares of Company stock on August 14, 2015 at prices ranging from \$569.11 to \$570.09. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 14, 2015 at each separate price.
- (2) Represents volume-weighted average price of sales of 3,603 shares of Company stock on August 14, 2015 at prices ranging from \$570.15 to \$571.09. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 14, 2015 at each separate price.
- (3) Represents volume-weighted average price of sales of 5,598 shares of Company stock on August 14, 2015 at prices ranging from \$571.14 to \$572.01. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 14, 2015 at each separate price.
- (4) Represents volume-weighted average price of sales of 2,800 shares of Company stock on August 14, 2015 at prices ranging from \$572.23 to \$573.06. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 14, 2015 at each separate price.
- (5) Represents volume-weighted average price of sales of 2,717 shares of Company stock on August 14, 2015 at prices ranging from \$573.15 to \$574.09. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 14, 2015 at each separate price.
- (6) Represents volume-weighted average price of sales of 900 shares of Company stock on August 14, 2015 at prices ranging from \$574.20 to \$575.10. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 14, 2015 at each separate price.
- (7) Represents volume-weighted average price of sales of 700 shares of Company stock on August 14, 2015 at prices ranging from \$575.30 to \$576.04. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 14, 2015 at each separate price.
- (8) Represents volume-weighted average price of sales of 2,004 shares of Company stock on August 14, 2015 at prices ranging from \$576.16 to \$577.09. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 14, 2015 at each separate price.
- (9) Represents volume-weighted average price of sales of 2,258 shares of Company stock on August 14, 2015 at prices ranging from \$577.24 to \$578.08. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 14, 2015 at each separate price.
- (10)

## Edgar Filing: REGENERON PHARMACEUTICALS INC - Form 4

Represents volume-weighted average price of sales of 1,500 shares of Company stock on August 14, 2015 at prices ranging from \$578.14 to \$579.07. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 14, 2015 at each separate price.

- (11) The stock option award (combined incentive stock option and non-qualified stock option) vests in four equal annual installments, commencing one year after the date of grant.
- (12) The option became exercisable with respect to all shares underlying the option on December 31, 2014, based upon the satisfaction by the company of certain performance criteria during the period ended December 31, 2014.
- (13) The stock option award vests in four equal annual installments, commencing one year after the date of grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.